Outlook Therapeutics Inc OTLK:NASDAQ

Last Price$1.33NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/14/22

Today's Change+0.03(2.31%)
Bid (Size)$1.29 (12)
Ask (Size)$1.35 (2)
Day Low / High$1.28 - 1.33
Volume1.6 M

View Biotechnology IndustryPeer Comparison as of 01/14/2022


Outlook Therapeutics Inc ( NASDAQ )

Price: $1.33
Change: +0.03 (2.31%)
Volume: 1.6 M
4:00PM ET 1/14/2022

Radius Health Inc ( NASDAQ )

Price: $6.40
Change: -0.05 (0.78%)
Volume: 1.4 M
4:00PM ET 1/14/2022

Alpine Immune Sciences Inc ( NASDAQ )

Price: $10.41
Change: +0.85 (8.89%)
Volume: 125.9 K
4:00PM ET 1/14/2022

Cardiff Oncology Inc ( NASDAQ )

Price: $6.86
Change: +0.04 (0.59%)
Volume: 477.0 K
4:00PM ET 1/14/2022


Price: $6.61
Change: +0.51 (8.36%)
Volume: 1.0 M
8:00PM ET 1/14/2022

Read more news Recent News

--Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating
10:26AM ET 12/27/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Buy: Outlook Therapeutics
6:18AM ET 12/02/2021 MT Newswires

Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....

Outlook Therapeutics Upsizes Bought-Deal Offering of Common Shares to $50 Million
6:14AM ET 11/24/2021 MT Newswires

Outlook Therapeutics (OTLK) on Tuesday increased its previously announced bought-deal offering of common shares to $50 million in gross proceeds from the...

Outlook Therapeutics Unveils $10 Million Common Stock Offering; Shares Sink
4:51PM ET 11/23/2021 MT Newswires

Outlook Therapeutics (OTLK) said late Tuesday it agreed to a bought-deal offering of common stock allowing underwriter HC Wainwright to buy 8 million...

View all Commentary and Analysis

Wall Street Breakfast: The Week Ahead (Podcast)
7:21AM ET 10/10/2021 Seeking Alpha

Wall Street Breakfast: The Week Ahead
7:03AM ET 10/10/2021 Seeking Alpha

Outlook Therapeutics (OTLK) Investor Presentation - Slideshow
3:40PM ET 10/01/2021 Seeking Alpha

Outlook Therapeutics (OTLK) Investor Presentation - Slideshow
1:38PM ET 8/23/2021 Seeking Alpha

Company Profile

Business DescriptionOutlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. View company web site for more details
Address485 Route 1 South
Iselin, New Jersey 08830
Number of Employees56
Recent SEC Filing12/23/202110-K
President, Chief Executive Officer & DirectorC. Russell Trenary
Chief Operating OfficerTerry Dagnon
CFO, Secretary, Treasurer & DirectorLawrence A. Kenyon
Senior Vice President-Clinical DevelopmentJennifer M. Kissner

Company Highlights

Price Open$1.30
Previous Close$1.30
52 Week Range$0.93 - 4.26
Market Capitalization$298.3 M
Shares Outstanding224.3 M
SectorHealth Technology
Next Earnings Announcement02/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.36
Beta vs. S&P 500N/A
Revenue$3.1 M
Net Profit MarginN/A
Return on Equity-772.36%

Analyst Ratings as of 01/05/2022

Consensus RecommendationConsensus Icon
Powered by Factset